The biologics safety testing market was valued at USD 2.75 Billion in 2017

The top four players in this market are Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany) and SGS SA (Switzerland) are. These companies have a broad product & service portfolio with comprehensive features and have a strong geographical presence.

By region, the global biologics safety testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016 followed by Europe, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; large population; growth in pharmaceutical and biotechnology industry; and growth in the outsourcing industry in this region are key factors driving the high growth of this regional segment.

For More Informartion : http://www.marketsandmarkets.com/pdfdownload.asp?id=34624144

Biologics safety testing is a mandatory process in pharmaceutical and biotechnological companies. It is used as a quality control measure for the drug development process. The biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% from 2017 to 2022. Growth in pharmaceutical and biotechnology industry driven by government support in both industries, the positive trend of R&D investment in the life sciences industry and an increase in the number of new drug launches are the major factors driving the growth of this market.

On the basis of products and services, the global market is segmented into kits & reagents, services, and instruments. The kits & reagents segment accounted for the largest share of the products segment. This growth can be attributed to the regular and repeated purchase of kits & reagents as compared to instruments.

On the basis of applications, the global market is segmented into vaccine and therapeutics development; blood and blood-related products testing; cellular and gene therapy; tissue and tissue-related products testing, and stem cell research.The vaccine and therapeutics development segment holds the largest share in the market. The growth of this segment is primarily attributed to the increase in initiatives for immunization, increase company investment in vaccines development and the rising prevalence of diseases.

Source: http://healthcareinterestingtrends.blogspot.in/2017/10/the-biologics-safety-testing-market-was.html

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s